July 19, 2022 01:24 PM EDT
Pharma
Manufacturing

WuXi Bi­o­log­ics serves up $1.4B ex­pan­sion of re­search and man­u­fac­tur­ing cen­ter in Sin­ga­pore

Tyler Patchen

News Reporter

While WuXi Bi­o­log­ics is con­tin­u­ing to work with US reg­u­la­tors on in­spec­tions of its fa­cil­i­ties, the com­pa­ny is al­so look­ing to ex­pand one of its …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

A service from the Financial Times